Related Experiment Video

Updated: Oct 3, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K

RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics

Poonam R Pandey1,2, Ken H Young3, Dhiraj Kumar4

  • 1Department of Thoracic & Cardio Surgery-Rsch, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.

Molecular Cancer
|February 22, 2022
PubMed

Insights

RNA-based immunotherapies show promise for targeting the tumor immune microenvironment (TIME) to combat cancer. These RNA therapeutics, by modulating TIME, offer a potential new avenue for cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • The tumor immune microenvironment (TIME) critically regulates tumor growth and metastasis.
  • The balance of immune-suppressive versus cytotoxic responses within the TIME impacts cancer progression.
  • Current cancer immunotherapies show variable clinical success, highlighting the need for novel strategies.

Purpose of the Study:

  • To review RNA-based cancer immunotherapies that target the TIME.
  • To summarize the clinical potential of diverse RNA-based therapeutics for cancer treatment.
  • To explore RNA-dependent targeting of the TIME as a future therapeutic approach.

Main Methods:

  • Literature review of current research on RNA-based immunotherapies.
  • Analysis of advancements in RNA technology for understanding the TIME.
  • Synthesis of data on clinically available RNA therapeutics for cancer.

Main Results:

  • RNA-based technologies enhance the understanding of TIME complexity and its therapeutic implications.
  • TIME-related RNA and RNA regulators are identified as potential targets for immunotherapy.
  • Various RNA-based therapeutics demonstrate clinical potential in cancer treatment.

Conclusions:

  • RNA-dependent targeting of the TIME represents a promising strategy for cancer immunotherapy.
  • Combining RNA-based therapies with other treatments may improve outcomes for cancer patients.
  • Future research should focus on the clinical application of RNA-based immunotherapies targeting the TIME.
Keywords:
AntibodyCancerCytokineDendritic cellsImmunotherapyNanoparticleRNARNA therapyT cellsTumor immune microenvironment

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

754
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

7.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
708
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
3.6K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
542